463 related articles for article (PubMed ID: 21081574)
21. The Role of Axillary SUV
Karabacak U; Turkan H; Coskun G; Mollaoglu MC; Hasbek Z; Karadayi K
J Coll Physicians Surg Pak; 2023 Apr; 33(4):374-379. PubMed ID: 37190706
[TBL] [Abstract][Full Text] [Related]
22. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
23. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
Shao M; Zi J; Wen G
J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
[TBL] [Abstract][Full Text] [Related]
24. Assessing
Sarikaya I; Sarikaya A
J Nucl Med Technol; 2019 Jun; 47(2):149-153. PubMed ID: 30413593
[No Abstract] [Full Text] [Related]
25. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
[TBL] [Abstract][Full Text] [Related]
26. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
[TBL] [Abstract][Full Text] [Related]
27. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
[TBL] [Abstract][Full Text] [Related]
28. Discordant results in
Parisse-Di Martino S; Faure C; Mognetti T
Cancer Treat Res Commun; 2021; 27():100344. PubMed ID: 33636590
[TBL] [Abstract][Full Text] [Related]
29. Reliability of predicting low-burden (≤ 2) positive axillary lymph nodes indicating sentinel lymph node biopsy in primary operable breast cancer - a retrospective comparative study with PET/CT and breast MRI.
Sae-Lim C; Wu WP; Chang MC; Lai HW; Chen ST; Chou CT; Liao CY; Huang HI; Chen ST; Chen DR; Hung CL
World J Surg Oncol; 2024 Jan; 22(1):12. PubMed ID: 38183069
[TBL] [Abstract][Full Text] [Related]
30. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
[TBL] [Abstract][Full Text] [Related]
31. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer.
Zornoza G; Garcia-Velloso MJ; Sola J; Regueira FM; Pina L; Beorlegui C
Eur J Surg Oncol; 2004 Feb; 30(1):15-9. PubMed ID: 14736517
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer.
Barranger E; Grahek D; Antoine M; Montravers F; Talbot JN; Uzan S
Ann Surg Oncol; 2003 Jul; 10(6):622-7. PubMed ID: 12839846
[TBL] [Abstract][Full Text] [Related]
34. A prospective comparative study of ultrasonography, contrast-enhanced MRI and 18F-FDG PET/CT for preoperative detection of axillary lymph node metastasis in breast cancer patients.
Guney IB; Dalci K; Teke ZT; Kucuker KA
Ann Ital Chir; 2020; 91():458-464. PubMed ID: 32213685
[TBL] [Abstract][Full Text] [Related]
35. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
[TBL] [Abstract][Full Text] [Related]
36. The predictive value, sensitivity, specificity, and accuracy of PET CT in the evaluation of axillary metastases in breast cancer.
Cetindag Ö; Avsar G; Hakseven M; Deryol R; Ertekin SÇ; Karasoy D; Eroglu A; Bayar S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10008-10015. PubMed ID: 37916371
[TBL] [Abstract][Full Text] [Related]
37. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
Heusner TA; Kuemmel S; Hahn S; Koeninger A; Otterbach F; Hamami ME; Kimmig KR; Forsting M; Bockisch A; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1543-50. PubMed ID: 19415270
[TBL] [Abstract][Full Text] [Related]
40. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
